Compounding BPC-157: A regulatory loophole In a statement, Health Canada said "BPC157 has not been authorized, its safety, efficacy, and quality have not been assessed and there is limited scientific evidence to support its use, including a lack of established human dosing protocols." In addition, the regulator says BPC-157 is not approved for use in any NHPs in any form, including oral and injectable, but it can still be compounded for topical use or oral administration as an NHP
How do you track your progress
Tanaka M, Hayashi N, Iida T, Kuzawa K, Naito M
(2) GLP-1R KO mice have reduced functional connectivity when measured across the whole brain
However, gastrointestinal side effects (nausea, constipation, diarrhea) still occur, typically mild to moderate in severity